The prognostic impact of MLH1 promoter hypermethylation in stage I–II endometrial cancer treated with adjuvant radiotherapy: a multi-institutional retrospective study MLH1ph status in stage I-II endometrial cancer
Sherwani Z, Damast S, Fields E, Beriwal S, Horne Z, Kidd E, Leung E, Taunk N, Chino J, Russo A, Dyer M, Albuquerque K, Hathout L. The prognostic impact of MLH1 promoter hypermethylation in stage I–II endometrial cancer treated with adjuvant radiotherapy: a multi-institutional retrospective study MLH1ph status in stage I-II endometrial cancer. International Journal Of Radiation Oncology • Biology • Physics 2025 PMID: 40379143, DOI: 10.1016/j.ijrobp.2025.05.004.Peer-Reviewed Original ResearchRecurrence-free survivalExternal beam radiationVaginal brachytherapyEndometrial cancerAssociated with decreased RFSAbsence of lymphovascular space invasionTreated with adjuvant radiation therapyPromoter hypermethylationStage I-II endometrial cancerProportion of locoregional recurrenceStage IMulti-institutional cohort studyAdjuvant radiation therapyLymphovascular space invasionInstitutional review board approvalPatterns of recurrenceKaplan-Meier methodReview board approvalDeficient mismatch repairMismatch repair statusAdjuvant radiotherapyCox proportional hazardsDistant recurrenceLocoregional recurrenceMyometrial invasion
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply